Modified Nucleic Acids: Replication, Evolution, and Next-Generation Therapeutics Karen Duffy†, Sebastian Arangundy-Franklin† and Philipp Holliger*

Total Page:16

File Type:pdf, Size:1020Kb

Modified Nucleic Acids: Replication, Evolution, and Next-Generation Therapeutics Karen Duffy†, Sebastian Arangundy-Franklin† and Philipp Holliger* Duffy et al. BMC Biology (2020) 18:112 https://doi.org/10.1186/s12915-020-00803-6 REVIEW Open Access Modified nucleic acids: replication, evolution, and next-generation therapeutics Karen Duffy†, Sebastian Arangundy-Franklin† and Philipp Holliger* Abstract Modified nucleic acids, also called xeno nucleic acids (XNAs), offer a variety of advantages for biotechnological applications and address some of the limitations of first-generation nucleic acid therapeutics. Indeed, several therapeutics based on modified nucleic acids have recently been approved and many more are under clinical evaluation. XNAs can provide increased biostability and furthermore are now increasingly amenable to in vitro evolution, accelerating lead discovery. Here, we review the most recent discoveries in this dynamic field with a focus on progress in the enzymatic replication and functional exploration of XNAs. Nucleic acids: natural and expanded functions afford completely new modalities for therapeutic inter- A heritable genetic system is a defining requirement for vention (e.g., direct protein expression or specific and life. The natural nucleic acids, DNA and RNA, are ex- programmable modulation of gene expression) that can- quisitely suited to store and propagate genetic informa- not be easily accessed by other biologics or small mol- tion with sufficient stability and fidelity to support large ecule drugs. However, several challenges have thus far genomes but also the flexibility to enable evolution. Nu- prevented nucleic acids from reaching their full potential cleic acids are unique among biopolymers in that both as medicines including poor chemical and biological accessible information and functional capacity coexist in stability and narrow chemical diversity. a single molecule. Thus, function can be evolved at the To address these limitations, DNA and RNA analogues molecular level yielding nucleic acid-based ligands and have been developed and evaluated for their ability to enzymes. In addition, nucleic acids fold through predict- serve as useful biomaterials or functional molecules, en- able and (to a large extent) programmable interactions, code genetic information, and support evolution. These are highly water-soluble, and can be easily denatured synthetic genetic polymers, broadly termed xeno nucleic and refolded. These advantages underpin their manifold acids (XNAs), exhibit modified backbones, sugars, or uses in biotechnology, diagnostics, therapeutics, nano- nucleobases, and even novel bases or base pairs [10, 11]. technology, material science, synthetic biology, and data While natural nucleic acids may also be modified to storage. modulate their function in vivo (e.g., post-synthetic epi- The last four decades have seen the rise of nucleic genetic modifications) [12–17], we constrain ourselves acids as therapeutics [1], primarily in the form of anti- here to a discussion of nucleic acid congeners not found sense oligonucleotides (ASOs) [2], small interfering in nature. We do, however, consider certain modifica- RNAs (siRNAs) [3], aptamers [4–6], microRNAs [7], tions that occur sporadically in natural oligonucleotides, mRNAs [8], and gene-editing guides [9]. Nucleic acids such as 2′OMe or C5 pyrimidine modifications, to be XNAs in the case of fully (or heavily) substituted oligo- * Correspondence: [email protected] nucleotides, the likes of which are not found in biology. †Karen Duffy and Sebastian Arangundy-Franklin contributed equally to this Several new and prominent XNA chemistries are shown work. in Fig. 1. One attractive feature of XNAs is their gener- MRC Laboratory of Molecular Biology, Cambridge Biomedical Campus, Francis Crick Avenue, Cambridge CB2 0QH, UK ally improved chemical and biological stability [18–20]. © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Duffy et al. BMC Biology (2020) 18:112 Page 2 of 14 Fig. 1 (See legend on next page.) Duffy et al. BMC Biology (2020) 18:112 Page 3 of 14 (See figure on previous page.) Fig. 1 The chemical diversity of XNAs. XNAs are often categorized by the component of the nucleotide (sugar, backbone, or base) carrying a modification. Shown here are XNAs discussed in this review, including both those of medical and historical relevance as well as several newly described chemistries. 2′F, 2′-fluoro; 2′OMe, 2′-O-methyl; LNA, locked nucleic acid; FANA, 2′-fluoro arabinose nucleic acid; HNA, hexitol nucleic acid; 2′MOE, 2′-O-methoxyethyl; ribuloNA, (1′-3′)-β-L-ribulo nucleic acid; TNA, α-L-threose nucleic acid; tPhoNA, 3′-2′ phosphonomethyl-threosyl nucleic acid; dXNA, 2′-deoxyxylonucleic acid; PS, phosphorothioate; phNA, alkyl phosphonate nucleic acid; PNA, peptide nucleic acid Decoration with diverse chemical substituents (e.g., demonstration of genetic function in an uncharged back- hydrophobic groups) can also yield improved properties bone chemistry for the first time as well as in vitro evo- and functionalities such as new structural motifs and en- lution of phNA aptamers [29]. hanced target binding [21–24]. While a wide range of As certain individual modifications become easier to XNAs have been synthesized at the chemical level, synthesize and their unique properties better under- representing a rich palette to draw from, their functional stood, combining two or more of these known modifica- potential and usage is only just beginning to be probed. tions to sugars, backbones, and bases will further push Here, we explore recent discoveries in the enzymatic the boundaries of chemical diversity in XNAs [30–35]. synthesis and functional exploration of XNAs with a The development of ever more diverse chemistries view towards therapeutic applications. raises the question: how much of what we know about natural nucleic acids translates to XNA? To what extent Expanding the chemistry of nucleic acids can we borrow design strategies from natural nucleic Advances in nucleic acid chemistry have enabled the de- acids in order to rapidly develop useful new XNA chem- velopment of XNAs with improved base-pairing stability istries? Some design rules, such as the ability of certain over natural nucleic acids as well as enhanced activity in sequence motifs to form G-quadruplexes, have been the context of living tissues, leading to several FDA ap- shown to translate to TNA [36] and FANA [37]. How- proved nucleic acid therapeutics [25]. Research con- ever, the generality of such parallels remains to be explored. tinues apace to identify novel chemistries with increased potency, bioavailability, stability, decreased toxicity, and Templated synthesis of non-natural nucleic acids minimal off-target effects. The phosphoramidite approach to solid-phase DNA syn- An interesting development in this context is the dis- thesis [38, 39] developed in the early 1980s led to the main- covery that mixed backbone chemistries can display stream use of synthetic DNA in a myriad of applications. novel emergent properties. For example, Krishnamurthy Similarly, improvements in the synthesis of XNAs can be and colleagues probed the ability of XNA-RNA chimeric expected to increase their usage and unlock new applica- oligonucleotides to hybridize with their natural nucleic tions in the coming decades. XNA synthesis can be broadly acid counterparts and found that the otherwise non- divided into enzymatic and non-enzymatic approaches. pairing ribuloNA can be interspersed with RNA or DNA Some widely used XNAs (e.g., 2′OMe, LNA, PS, 2′MOE) building blocks to yield oligonucleotides with compar- can be chemically synthesized, although yields of even the able or higher duplex thermal stability than natural sys- most synthetically accessible XNAs are limited to around tems and tuneable base-pairing properties [26]. The 150 bp [40]. For other XNA chemistries, no reliable solid- authors suggest that such a system could be used to phase synthetic route is known [41]. Furthermore, solid- mimic natural base-pairing rules with a reduced number phase synthesis depends on explicit knowledge of the se- of bases, storing information in the sugar in place of the quence being synthesized. In contrast, templated synthesis GC base pair. enables general information transfer and is essential for the Similarly, the recent discovery that smaller “skinny” evolution of functional oligonucleotides. (pyrimidine-like) and larger “fat” (purine-like) base pairs can form stable helices challenges conventional assump- Non-enzymatic templated synthesis tions of nucleic acid structure [27]. While the novel base Non-enzymatic templated synthesis
Recommended publications
  • Nucleoside Phosphate-Conjugates Come of Age: Catalytic Transformation, Polymerase Recognition and Antiviral Properties.# Elisabetta Groaz* and Piet Herdewijn
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Lirias Send Orders for Reprints to [email protected] Current Medicinal Chemistry, Year, Volume 1 Nucleoside Phosphate-Conjugates Come of Age: Catalytic Transformation, Polymerase Recognition and Antiviral Properties.# Elisabetta Groaz* and Piet Herdewijn Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium Abstract: Over the past few decades, different types of nucleoside phosphate-conjugates have been under extensive investigation due to their favorable molecular lability with interesting catalytic hydrolysis mechanisms, recognition as polymerase substrates, and especially for their development as antiviral/anticancer protide therapeutics. The antiviral conjugates such as nucleoside phosphoesters and phosphoramidates that were discovered and developed in the initial years have been well reviewed by the pioneers in the field. In the present review, we will discuss the basic chemical and biological principles behind consideration of some representative structural classes. We will also summarize the chemical and biological properties of some of the more recent analogues that were synthesized and evaluated in our laboratory and by others. This includes new principles for their application as direct substrates of polymerases, nucleobase-dependent catalytic and antiviral activity, and a plausible ‘prodrug of a prodrug’ strategy for tissue/organ-specific targeted drug delivery. Keywords: Prodrug – Delivery – Stability – Polymerase - Phosphoramidates INTRODUCTION profile of these molecules through the “tuning” of the nature of the existing ligands and the pursuit of new protecting The ability of unnatural nucleoside-based therapeutics to moieties relying on chemical rather than enzymatic induce inhibition of uncontrolled cell proliferation or viral dependant activation mechanisms.
    [Show full text]
  • Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules
    MEDICAL INTELLIGENCE UNIT Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules Christopher G. Janson, M.D. Departments of Neurosurgery, Neurology and Molecular Genetics Cell and Gene Therapy Center UMDNJ-Robert Wood Johnson Medical School Camden, New Jersey, U.S.A. Matthew J. During, M.D., ScD. Department of Molecular Medicine and Pathology University of Auckland Auckland, New Zealand LANDES BIOSCIENCE / EUREKAH.COM KLUWER ACADEMIC / PLENUM PUBLISHERS GEORGETOWN, TEXAS NEW YORK, NEW YORK USA U.SA PEPTIDE NUCLEIC ACIDS, MORPHOLINOS AND RELATED ANTISENSE BIOMOLECULES Medical Intelligence Unit Landes Bioscience / Eurekah.com Kluwer Academic / Plenum Publishers Copyright ©2006 Eurekah.com and Kluwer Academic / Plenum Publishers All rights reserved. No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher, vdth the exception of any material supplied specifically for the purpose of being entered and executed on a computer system; for exclusive use by the Purchaser of the work. Printed in the U.S.A. Kluwer Academic / Plenum PubHshers, 233 Spring Street, New York, New York, U.S.A. 10013 http ://www.wkap .nl/ Please address all inquiries to the Publishers: Landes Bioscience / Eurekah.com, 810 South Church Street, Georgetown, Texas, U.S.A. 78626 Phone: 512/ 863 7762; FAX: 512/ 863 0081 http ://v^^ww.eurekah. com http://www.landesbioscience.com Peptide
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,598.458 B2 Shimizu Et Al
    USO09598458B2 (12) United States Patent (10) Patent No.: US 9,598.458 B2 Shimizu et al. (45) Date of Patent: Mar. 21, 2017 (54) ASYMMETRICAUXILLARY GROUP 3,687,808 A 8/1972 Merigan et al. 3,745,162 A 7/1973 Helsley 4,022,791 A 5/1977 Welch, Jr. (71) Applicant: NYTE SCIENCES JAPAN, 4,113,869 A 9, 1978 Gardner ... Kagoshima-shi (JP) 4.415,732 A 1 1/1983 Caruthers et al. 4,458,066 A 7/1984 Caruthers et al. (72) Inventors: Mamoru Shimizu, Uruma (JP); 4,500,707 A 2f1985 Caruthers et al. Takeshi Wada, Kashiwa (JP) 4,542,142 A 9, 1985 Martel et al. 4,659,774 A 4, 1987 Webb et al. 4,663,328 A 5, 1987 Lafon (73) Assignee: YESCIENCES JAPAN, 4,668,777. A 5/1987 Caruthers et al. ... Kagoshima-shi (JP) 4,725,677 A 2/1988 Koster et al. 4,735,949 A 4, 1988 Domagala et al. (*) Notice: Subject to any disclaimer, the term of this 4,840,956 A 6/1989 Domagala et al. patent is extended or adjusted under 35 3:38 A . 3. EthOester Phet al. et al. U.S.C. 154(b) by 17 days. 4,973,679 A 1 1/1990 Caruthers et al. 4,981,957 A 1/1991 Lebleu et al. (21) Appl. No.: 14/414,604 5,047,524. A 9/1991 Andrus et al. 5,118,800 A 6/1992 Smith et al. (22) PCT Filed: Jul. 12, 2013 5,130,302 A 7/1992 Spielvogel et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0203610 A1 Meller Et Al
    US 20130203610A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0203610 A1 Meller et al. (43) Pub. Date: Aug. 8, 2013 (54) TOOLS AND METHOD FOR NANOPORES Related U.S. Application Data UNZIPPING-DEPENDENT NUCLECACID (60) Provisional application No. 61/318,872, filed on Mar. SEQUENCING 30, 2010. (75) Inventors: Amit Meller, Brookline, MA (US); Alon Publication Classification Singer, Brighton, MA (US) (51) Int. Cl. (73) Assignee: TRUSTEES OF BOSTON CI2O I/68 (2006.01) UNIVERSITY, Boston, MA (US) (52) U.S. Cl. CPC .................................... CI2O I/6874 (2013.01) (21) Appl. No.: 13/638,455 USPC ................................................. 506/6:506/16 (57) ABSTRACT (22) PCT Filed: Mar. 30, 2011 Provided herein is a library that comprises a plurality of molecular beacons (MBs), each MB having a detectable (86). PCT No.: PCT/US2O11AO3O430 label, a detectable label blocker and a modifier group. The S371 (c)(1), library is used in conjunction with nanopore unzipping-de (2), (4) Date: Apr. 17, 2013 pendent sequencing of nucleic acids. Patent Application Publication Aug. 8, 2013 Sheet 1 of 18 US 2013/020361.0 A1 . N s Patent Application Publication Aug. 8, 2013 Sheet 2 of 18 US 2013/020361.0 A1 I’9IAI ::::::::::: Dº3.modoueN Patent Application Publication Aug. 8, 2013 Sheet 3 of 18 US 2013/020361.0 A1 Z’9IAI ~~~~~~~~~);........ Patent Application Publication Aug. 8, 2013 Sheet 4 of 18 US 2013/020361.0 A1 s :·.{-zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz iii. 9 iii.338 lii &S Patent Application Publication Aug. 8, 2013 Sheet 5 of 18 US 2013/020361.0 A1 s r Patent Application Publication Aug.
    [Show full text]
  • Depression of Thymidylate Synthetase Activity in Response to Cytosine Arabinoside1
    [CANCER RESEARCH 32, 1160-1169, June 1972] Depression of Thymidylate Synthetase Activity in Response To Cytosine Arabinoside1 DeWayne Roberts and Ellen V. Loehr St. Jude Children's Research Hospital, Memphis, Tennessee 38101 ¡D.R., E. V. L.J and Department of Pharmacology, University of Tennessee Medical Units, Memphis, Tennessee 38101 [D. R.J SUMMARY Cytosine arabinoside induces remission of acute granulocytic leukemia (11). After the administration of Depression of thymidylate synthetase activity by cytosine cytosine arabinoside to patients, changes in the enzyme arabinoside in CCRF-CEM cells was correlated with a blocking activity pattern of leukemic leukocytes occur (32). After drug of precursor incorporation into RNA and with cell lysis. With administration, a decrease in thymidylate synthetase activity is increasing concentrations of cytosine arabinoside in the observed as early as 1 hr and persists for 24 hr in some culture media, a proportional decrease of uridine patients. A concentration-dependent decrease in thymidylate incorporation into RNA and decrease in thymidylate synthetase activity also follows the addition of cytosine synthetase activity occurred and was accompanied by lysis of arabinoside to CCRF-CEM cultures (33). the cells. These effects continued to develop with drug Methotrexate elevates thymidylate synthetase activity in concentrations in excess of that required to block thymidine leukocytes from patients with acute leukemia (32), in rat liver incorporation into DNA. The addition of deoxycytidine at and transplantable tumors (27), and in cells of LI210 or concentrations that failed to reverse inhibition by cytosine CCRF-CEM cultures (32, 33). The simultaneous addition of arabinoside of thymidine incorporation into DNA reversed the cytosine arabinoside and methotrexate to CCRF-CEM cultures drug effects on uridine incorporation, thymidylate synthetase modulated the effect of each drug on thymidylate synthetase activity, and cell lysis.
    [Show full text]
  • 2'-Deoxyguanosine Toxicity for B and Mature T Lymphoid Cell Lines Is Mediated by Guanine Ribonucleotide Accumulation
    2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation. Y Sidi, B S Mitchell J Clin Invest. 1984;74(5):1640-1648. https://doi.org/10.1172/JCI111580. Research Article Inherited deficiency of the enzyme purine nucleoside phosphorylase (PNP) results in selective and severe T lymphocyte depletion which is mediated by its substrate, 2'-deoxyguanosine. This observation provides a rationale for the use of PNP inhibitors as selective T cell immunosuppressive agents. We have studied the relative effects of the PNP inhibitor 8- aminoguanosine on the metabolism and growth of lymphoid cell lines of T and B cell origin. We have found that 2'- deoxyguanosine toxicity for T lymphoblasts is markedly potentiated by 8-aminoguanosine and is mediated by the accumulation of deoxyguanosine triphosphate. In contrast, the growth of T4+ mature T cell lines and B lymphoblast cell lines is inhibited by somewhat higher concentrations of 2'-deoxyguanosine (ID50 20 and 18 microM, respectively) in the presence of 8-aminoguanosine without an increase in deoxyguanosine triphosphate levels. Cytotoxicity correlates instead with a three- to fivefold increase in guanosine triphosphate (GTP) levels after 24 h. Accumulation of GTP and growth inhibition also result from exposure to guanosine, but not to guanine at equimolar concentrations. B lymphoblasts which are deficient in the purine salvage enzyme hypoxanthine guanine phosphoribosyltransferase are completely resistant to 2'-deoxyguanosine or guanosine concentrations up to 800 microM and do not demonstrate an increase in GTP levels. Growth inhibition and GTP accumulation are prevented by hypoxanthine or adenine, but not by 2'-deoxycytidine.
    [Show full text]
  • Excited State Dynamics of Isocytosine; a Hybrid Case of Canonical Nucleobase Photodynamics
    The Journal of Physical Chemistry Letters This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies. Excited State Dynamics of Isocytosine; a Hybrid Case of Canonical Nucleobase Photodynamics Journal: The Journal of Physical Chemistry Letters Manuscript ID jz-2017-020322.R1 Manuscript Type: Letter Date Submitted by the Author: n/a Complete List of Authors: Berenbeim, Jacob; UC Santa Barbara, Chemistry and Biochemistry Boldissar, Samuel; UCSB, Department of Chemistry Siouri, Faady; UCSB, Department of Chemistry Gate, Gregory; UCSB, Department of Chemistry Haggmark, Michael; UC Santa Barbara, Chemistry and Biochemistry Aboulache, Briana; University of California Santa Barbara Cohen, Trevor; UC Santa Barbara, Chemistry and Biochemistry De Vries, Mattanjah; UCSB, Department of Chemistry ACS Paragon Plus Environment Page 1 of 12 The Journal of Physical Chemistry Letters 1 2 3 4 Excited State Dynamics of Isocytosine; A Hybrid Case of Canonical 5 Nucleobase Photodynamics 6 7 Jacob A. Berenbeim, Samuel Boldissar, Faady M. Siouri, Gregory Gate, Michael R. 8 Haggmark, Briana Aboulache, Trevor Cohen, and Mattanjah S. de Vries* 9 10 Department of Chemistry and Biochemistry, University of California Santa 11 12 Barabara, CA 93106-9510 13 *E-mail: [email protected] 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 ACS Paragon Plus Environment The Journal of Physical Chemistry Letters Page 2 of 12 1 2 3 Abstract 4 5 We present resonant two-photon ionization (R2PI) spectra of isocytosine (isoC) and pump-probe 6 results on two of its tautomers.
    [Show full text]
  • Alternative Biochemistries for Alien Life: Basic Concepts and Requirements for the Design of a Robust Biocontainment System in Genetic Isolation
    G C A T T A C G G C A T genes Review Alternative Biochemistries for Alien Life: Basic Concepts and Requirements for the Design of a Robust Biocontainment System in Genetic Isolation Christian Diwo 1 and Nediljko Budisa 1,2,* 1 Institut für Chemie, Technische Universität Berlin Müller-Breslau-Straße 10, 10623 Berlin, Germany; [email protected] 2 Department of Chemistry, University of Manitoba, 144 Dysart Rd, 360 Parker Building, Winnipeg, MB R3T 2N2, Canada * Correspondence: [email protected] or [email protected]; Tel.: +49-30-314-28821 or +1-204-474-9178 Received: 27 November 2018; Accepted: 21 December 2018; Published: 28 December 2018 Abstract: The universal genetic code, which is the foundation of cellular organization for almost all organisms, has fostered the exchange of genetic information from very different paths of evolution. The result of this communication network of potentially beneficial traits can be observed as modern biodiversity. Today, the genetic modification techniques of synthetic biology allow for the design of specialized organisms and their employment as tools, creating an artificial biodiversity based on the same universal genetic code. As there is no natural barrier towards the proliferation of genetic information which confers an advantage for a certain species, the naturally evolved genetic pool could be irreversibly altered if modified genetic information is exchanged. We argue that an alien genetic code which is incompatible with nature is likely to assure the inhibition of all mechanisms of genetic information transfer in an open environment. The two conceivable routes to synthetic life are either de novo cellular design or the successive alienation of a complex biological organism through laboratory evolution.
    [Show full text]
  • Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide
    ICANCER RESEARCH 26 Part 1, 1466-1472,July 1966] Deoxyribonucleic Acid Synthesis I. Effect of in Vivo Cyclophosphamide Treatment on the in Vitro Activity of the Deoxyribonucleic Acid Synthetase System of Sensitive and Resistant Plasmacytomas1 ARTHUR J. TOMISEK, MARTHA BRUCE IRICK, AND PAULA WEDELES ALLAN Kettering'-Meyer Laboratory,2 Southern Research Institute, Birmingham, Alabama Summary term DNA-synthetase. In addition to this measurement of over-all DNA synthetase activity, we used the same experiments We have shown that the in vivo treatment of Fortner plasma- to determine the time course of radioactivity distribution among cytomas with Cyclophosphamide can lead to strong inhibitions of both deoxyribonucleic acid nucleotidyl transferase and thymi- the soluble components of the synthetase reaction mixtures. Our data show that the observed decreases in enzyme activity dylatc kinase activities in the soluble cell fractions. However, in are among the possible consequences of growth inhibition in the allowing only 2 hr for the inhibitor to act, the effect observed on tumor. the transferase was an unexplained stimulation rather than an inhibition. We have also provided some evidence that the inhibition of Materials and Methods growth precedes the inhibition of deoxyribonucleic acid nucleo ENZYME PREPARATION.Fortner hamster plasmacytoma tidyl transferase activity. ("sensitive") (3) and ite cyclophosphamide-resistant subline (12) were used for bilateral s.c. implantation into groups of 6-12 Introduction Golden Syrian hamsters, the animals in each experiment being uniform with respect to commercial subline, sex, and approxi Previous studies in this laboratory have shown that several mate age. On the 12th-14th postimplant day the animals were alkylating agents inhibited the in vivo synthesis of DNA by divided into 2 subgroups, to receive daily i.p.
    [Show full text]
  • On-Demand Synthesis of Phosphoramidites
    ARTICLE https://doi.org/10.1038/s41467-021-22945-z OPEN On-demand synthesis of phosphoramidites Alexander F. Sandahl1, Thuy J. D. Nguyen1, Rikke A. Hansen1, Martin B. Johansen 1, Troels Skrydstrup 1,2 & ✉ Kurt V. Gothelf 1,2 Automated chemical synthesis of oligonucleotides is of fundamental importance for the production of primers for the polymerase chain reaction (PCR), for oligonucleotide-based drugs, and for numerous other medical and biotechnological applications. The highly opti- mised automised chemical oligonucleotide synthesis relies upon phosphoramidites as the 1234567890():,; phosphate precursors and one of the drawbacks of this technology is the poor bench stability of phosphoramidites. Here, we report on the development of an on-demand flow synthesis of phosphoramidites from their corresponding alcohols, which is accomplished with short reaction times, near-quantitative yields and without the need of purification before being submitted directly to automated oligonucleotide synthesis. Sterically hindered as well as redox unstable phosphoramidites are synthesised using this methodology and the sub- sequent couplings are near-quantitative for all substrates. The vision for this technology is direct integration into DNA synthesisers thereby omitting manual synthesis and storage of phosphoramidites. 1 Interdisciplinary Nanoscience Center, iNANO, Aarhus University, Aarhus C, Denmark. 2 Department of Chemistry, Aarhus University, Aarhus C, Denmark. ✉ email: [email protected] NATURE COMMUNICATIONS | (2021) 12:2760 | https://doi.org/10.1038/s41467-021-22945-z | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22945-z ynthetic oligonucleotides are essential for a range of dif- includetheuseofmechanochemistry11 or the use of P(V) chemistry Sferent areas and millions of oligonucleotides are synthesized to form the internucleosidic P–Obond12,13.
    [Show full text]
  • Structure and Function Of
    8/5/2019 DNA and RNA The Code of Life The Human Genome Project Gene Expression Genetic code The alphabet of the genetic code contains Genes are DNA sequences that encode proteins (the gene product) only four letters (A,T,G,C). Gene expression refers to the process A number of experiments confirmed that the whereby the information contained in genes genetic code is written in 3-letter words, each begins to have effects in the cell. of which codes for particular amino acid. DNA encodes and transmits the genetic A nucleic acid word (3 nucleotide letters) is information passed down from parents to offspring. referred to as a codon. 1 8/5/2019 Nucleic acids Nucleotides Principle information molecule in the Nucleotides are the unit structure of cell. nucleic acids. Nucleotides composed of 3 All the genetic codes are carried out on components: the nucleic acids. Nitrogenous base (A, C, G, T or U) Pentose sugar Nucleic acid is a linear polymer of Phosphate nucleotides Nucleotides Nitrogenous bases There are four nitrogen bases making up four different nucleotides. There are 2 types: Purines(pyoo r-een): Adenine A Two ring structure Purines Adenine (A) and Guanine (G) Guanine G Pyrimidines(pahy-rim-i-deen,): N base Single ring structure Cytosine (C) and Thymine (T) or Uracil (U). Thymine T Pyrimidines Cytosine C 2 8/5/2019 A NUCLEOTIDE Nucleotide bases 1. Phosphate Group 2.3. 5Nitrogen-Carbon BaseSugar 1. Phosphate Group 2. 5-Carbon Sugar (Dexoyribose or Ribose) 3. (Dexoyribose or Ribose) 1. 3. Nitrogen Base 2. 3. Nucleotides, too O 1.
    [Show full text]
  • Nucleic Acids Research
    Volume 1 1 Number 4 1983 Nucleic Acids Research Isolation and nudeotide sequence of a plant tRNA gene: petunia asparagine tRNA Nurit Bawnik, Jacques S.Beckmann*, Sara Sarid + and Violet Daniel Departments of Biochemistry and + Biophysics, The Weizmann Institute of Science, Rehovot 76100, Israel, and *Institute of Field and Garden Crops, The Volcani Center, Bet Dagan 50200, Israel Received 29 October 1982; Revised and Accepted 18 January 1983 ABSTRACT A 14.3 kb petunia genomic DNA fragment was isolated and found to contain a single tRNA gene coding for asparagine tRNA. The nucleotide sequence of the asparagine tRNA gene and its flanking regions has been determined. This gene does not contain intervening sequences nor the 3'-end CCA sequence of the ma- ture tRNA and presents a similar overall sequence homology (70%) to both E. coli and mammalian asparagine tRNA. As in other eukaryotic tRNA genes the 5'-flanking region does not seem to contain any special sequence that could function as a regulatory element and the 3'-end is followed by a short cluster of T that may function as the transcription termination site. INTRODUCTION In contrast to the large amount of information that has been accumulated on the arrangement and structure of tRNA genes from a variety of eukaryotes such as yeast, Neurospora, Bombyx, Xenopus, Drosophila, rat and man (1-13), nothing is known about plant nuclear tRNA genes. To study genes for tRNA in plant cells, we have constructed a petunia genomic library and screened it with an unfractionated cytoplasmic petunia tRNA probe. Here we describe the detailed analysis of a tRNA gene-containing clone and the nucleotide se- Asn quence of a DNA fragment carrying a tRNAMKC(U) gene.
    [Show full text]